Literature DB >> 9551738

Prevalence of bronchial hyperresponsiveness to 4.5% saline and its relation to asthma and allergy symptoms in Austrian children.

J Riedler1, A Gamper, W Eder, G Oberfeld.   

Abstract

The prevalence of asthma in school children has been reported to have increased, with wide variations between countries. To allow comparison of prevalence data, objective markers of asthma should be measured. Therefore, we assessed the prevalence of bronchial hyperresponsiveness (BHR) to hypertonic saline and its relation to asthma and allergy symptoms in 507 Austrian school children, aged 12-15 yrs in a cross-sectional, community based survey. These children were selected from 3,371 children who had answered a self-administered written questionnaire on asthma, hay fever, eczema and environmental factors. The prevalence of BHR to hypertonic saline was 14% and the majority (70%) of the children had mild BHR. The prevalence of wheeze in the last 12 months was 12% and of a diagnostic label of asthma was 6%. Fifty three per cent of the children with symptoms in the last 12 months and a diagnostic label of asthma had BHR, and 33% of those with symptoms in the last 12 months regardless of a diagnostic label of asthma showed a positive response to hypertonic saline. Atopic dermatitis, a diagnostic label of asthma, night cough apart from colds, wheeze in the past 12 months (but not "former wheeze") and male gender were significantly associated with increased response to 4.5% saline in the final logistic regression model. These results show that the prevalence of asthma symptoms in the last 12 months and the prevalence of bronchial hyperresponsiveness to hypertonic saline are twice that of a diagnosis of asthma and that asthma might be underdiagnosed in the present population. The response to hypertonic saline is most strongly associated with current asthma and allergy symptoms. A combination of a "diagnostic label of asthma" and "asthma symptoms in the last 12 months" might best reflect "current asthma" in epidemiological studies in this population.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9551738     DOI: 10.1183/09031936.98.11020355

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  5 in total

1.  Cysteinyl leukotriene antagonism inhibits bronchoconstriction in response to hypertonic saline inhalation in asthma.

Authors:  Shamsah Kazani; Jonathan Sadeh; Sreedhar Bunga; Michael E Wechsler; Elliot Israel
Journal:  Respir Med       Date:  2010-12-18       Impact factor: 3.415

2.  Comparison of 4 AM and 4 PM bronchial responsiveness to hypertonic saline in asthma.

Authors:  Erica Ferraz; Marcos C Borges; J Terra-Filho; José A B Martinez; Elcio O Vianna
Journal:  Lung       Date:  2006-11-03       Impact factor: 2.584

Review 3.  Methods for "indirect" challenge tests including exercise, eucapnic voluntary hyperpnea, and hypertonic aerosols.

Authors:  Sandra D Anderson; John D Brannan
Journal:  Clin Rev Allergy Immunol       Date:  2003-02       Impact factor: 8.667

4.  The safety and efficacy of inhaled dry powder mannitol as a bronchial provocation test for airway hyperresponsiveness: a phase 3 comparison study with hypertonic (4.5%) saline.

Authors:  John D Brannan; Sandra D Anderson; Clare P Perry; Ruth Freed-Martens; Anna R Lassig; Brett Charlton
Journal:  Respir Res       Date:  2005-12-09

Review 5.  'Indirect' challenges from science to clinical practice.

Authors:  Sandra D Anderson
Journal:  Eur Clin Respir J       Date:  2016-02-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.